Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly’s Zyprexa, Cymbalta Will Be Dropped From Florida Medicaid Drug List

Executive Summary

Florida Medicaid will reconsider the status of GlaxoSmithKline's Paxil, Forest's Lexapro and Pfizer's Zoloft on the state's preferred drug list in September after awarding the antidepressants conditional placement on the PDL

You may also be interested in...



Pfizer Lipitor, Detrol Removed From Florida Medicaid Preferred Drug List

Florida Medicaid recipients will have to try at least two other drugs in the same category before they are allowed to receive any of six Pfizer drugs recently removed from the state's preferred drug list

Pfizer Lipitor, Detrol Removed From Florida Medicaid Preferred Drug List

Florida Medicaid recipients will have to try at least two other drugs in the same category before they are allowed to receive any of six Pfizer drugs recently removed from the state's preferred drug list

Florida Medicaid

Florida Medicaid's preferred drug list will include Pfizer's Zoloft, Forest's Lexapro and GlaxoSmithKline's Paxil CR, Wellbutrin XL and Lamictal after the manufacturers renegotiated prices for the mental health products. The drugs were not initially recommended for inclusion by the Florida pharmacy & therapeutics committee under revisions to the Medicaid PDL (1"The Pink Sheet" July 11, 2005, p. 11). Wyeth's Effexor XR and Lilly's antidepressants (Cymbalta, Prozac Weekly, Sarafem) and antipsychotics (Zyprexa and Symbyax) are among the products that will require prior authorization...

Related Content

Topics

UsernamePublicRestriction

Register

ID1131516

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel